@article{aa32b96ef67c47b5b358385c5c9e4994,
title = "Novel immune checkpoint blocker approved for the treatment of advanced melanoma",
keywords = "CTLA4, Keytruda{\texttrademark}, PD-1, Yervoy{\texttrademark}, ipilimumab, nivolumab",
author = "Lorenzo Galluzzi and Guido Kroemer and Alexander Eggermont",
note = "Funding Information: Authors are supported by Ligue contre le Cancer ({\'e}quipe labelis{\'e}e); Agence National de la Recherche (ANR); Associa tion pour la recherche sur le cancer (ARC); Canc{\'e}rop{\^o}le Ile-de-France; AXA Chair for Longevity Research; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche M{\'e}dicale (FRM); the European Commis sion (ArtForce); the European Research Council (ERC); the LabEx Immuno- Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medi cine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).",
year = "2014",
month = nov,
day = "2",
doi = "10.4161/21624011.2014.967147",
language = "English",
volume = "3",
pages = "e967147--1--e967147--5",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor and Francis Ltd.",
number = "11",
}